Skip to main content
OpenTrials
Completed

NCT Number: NCT03438227

Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial

Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. While treatment of iron-deficiency anemia with iron supplementation is recommended, treatment strategies remain controversial: the American College of Obstetrics and Gynecology recommends oral iron supplementation with parental iron reserved for the rare patient who cannot tolerate or will not take oral iron, while United Kingdom professional organizations recommend a more liberal use of parenteral iron. The reason for these disparate recommendations is that few high-quality studies comparing oral to parenteral iron have been conducted in developed countries, and the potential impact of parental iron treatment on obstetric and perinatal outcomes remains unclear. We propose the first randomized-controlled trial in the United States describing the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Indiana University School of Medicine, Indianapolis, Indiana, United States

Loading trial locations.

About this study

Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. In the United States, anemia affects nearly 20% of pregnancies and the majority is iron-deficiency anemia. Therefore, treatment of iron-deficiency anemia with iron supplementation is recommended.1 However, there is controversy about the treatment strategies.

The American College of Obstetrics and Gynecology recommends oral iron supplementation for iron-deficiency anemia in pregnancy, with parental iron reserved only for the "rare patient who cannot tolerate or will not take oral iron" (1) Conversely, guidelines from the United Kingdom. are more liberal on the use of parental iron for the treatment of iron-deficiency anemia in pregnancy (2). Both treatment guidelines are based on limited data regarding the risks and benefits of parental iron for treatment of iron-deficiency anemia in pregnancy. The majority of randomized trials were conducted in developing country settings. In fact, few high-quality studies have been conducted in developed countries, and none has been conducted in the United States Moreover, there is limited data from prior studies on the impact of parental iron treatment on perinatal outcomes. The most recent Cochrane review including mostly from trials conducted in low-income countries found that, although parenteral iron improved hemoglobin levels and iron stores than the oral route, no clinical outcomes were assessed and there were insufficient data on adverse effects (3). The authors concluded that "large, good quality trials, assessing clinical outcomes including adverse effects … are required" (3).

This randomized controlled trial aims to assess the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron. We hypothesize that treating iron-deficiency anemia with parental iron is associated with improved maternal and neonatal outcomes compared with a protocol based on oral iron. To increase generalizability of the findings, we will use broad inclusion criteria and analyze data using the intention-to-treat principle.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Iron-deficiency anemia (serum ferritin <30 micrograms, normal hemoglobin electrophoresis, and hemoglobin <10 mg/dL), planned delivery at Barnes-Jewish Hospital

Exclusion criteria

  • Non-iron-deficiency anemia, multiple gestation, prenatally diagnosed major fetal anomalies, known aneuploidy, planned delivery at other hospital, inability to obtain consent

Treatment and study plan

Iron Dextran

Drug

Single intravenous infusion of iron dextran 1000mg.

Other names: Experimental

Ferrous sulfate 325mg

Drug

Oral iron supplementation with ferrous sulfate 325mg one to three times daily

Other names: Active comparator

Primary outcomes

  1. Maternal Anemia at Delivery

    Time frame: At delivery

    Number of participants with maternal hemoglobin <11g/dl at delivery

Secondary outcomes

  1. Maternal Hemoglobin at Delivery

    Time frame: On admission to inpatient obstetrics unit for delivery

    Maternal hemoglobin on admission to inpatient obstetrics unit for delivery

  2. Number of Participants With Medication Adverse Events

    Time frame: 2 - 3 days after single intravenous iron infusion or initiation of oral iron

    Participants reporting symptoms when contacted by via telephone 2 - 3 days after their infusion of intravenous iron or initiation of oral iron

  3. Maternal Hemoglobin Below 10g/dl at Delivery

    Time frame: At delivery

    Number of participants with hemoglobin below 10g/dl at delivery

  4. Maternal Ferritin at Delivery

    Time frame: At delivery

    Maternal serum ferritin level in μg/L at delivery

  5. Number of Participants Who Received Blood Transfusion

    Time frame: During inpatient admission for delivery of neonate

    Participant receiving transfusion of packed red blood cells during admission for delivery of infant obtained via medical chart review.

  6. Mode of Delivery

    Time frame: Once, at infant delivery

    Whether infant was delivered vaginally or via cesarean section

  7. Gestational Age at Delivery

    Time frame: Once, at infant delivery

    Gestational age in weeks at delivery

  8. Birth Weight

    Time frame: Obtained once, at infant delivery

    Neonatal weight at delivery

  9. Umbilical Cord Arterial pH

    Time frame: Drawn once from umbilical cord segment at delivery

    Umbilical cord arterial pH obtained at delivery

  10. APGAR Scores at 1 Minutes of Life

    Time frame: Obtained at 1 minute of life

    The APGAR score, named after the Virginia Apgar, pediatrician who came up with it, measures the physical condition of a newborn infant on a scale ranging from a minimum of 0 (worsts) to a maximum of 10 (best).

  11. Neonatal Hemoglobin

    Time frame: Drawn once from umbilical cord segment at birth

    Neonatal hemoglobin in g/dl at delivery

  12. Composite Neonatal Morbidity (Defined by the Occurrence of One or More of 10 Neonatal Morbidities.

    Time frame: At birth

    Neonatal morbidity composite, defined by the occurrence of one or more of the following neonatal morbidities: neonatal seizures (diagnosed by clinician), intraventricular hemorrhage (diagnosed by clinician on brain MRI or Ultrasound), hypoxic-ischemic encephalopathy (diagnosed by clinician), neonatal hypothermic therapy (brain cooling as documented on inpatient record, sepsis (diagnosed by blood culture), respiratory distress syndrome (diagnosed by clinician), hyperbilirubinemia requiring photo therapy (diagnosed by clinician), birth injury (diagnosed by clinician), or meconium aspiration syndrome (diagnosed by clinician), neonatal intensive care unit admission (documented in the inpatient record).

  13. Neonatal Ferritin

    Time frame: Drawn once from umbilical cord segment at birth

    Neonatal ferritin in ug/L at delivery

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Registry information

Acronym: IVIDA

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Feb 19, 2018
Registry last updated
Jun 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.